WSI's operating profit for the third quarter of this year rose 71.9% year over year to KRW 870 million.


WSI's Q3 Operating Profit Rises 71.9% YoY to KRW 870 Million View original image

WSI said on November 16 that revenue fell 2.0% year over year to KRW 7.95 billion. On a cumulative standalone basis, operating profit for the first three quarters rose 11.2% year over year to KRW 2 billion, while revenue increased 0.2% to KRW 23.6 billion.


Cumulative revenue from Oxyflex, one of the company's key products, rose 20.1% year over year to KRW 1.7 billion in the first three quarters. Flosil also maintained steady sales. In addition, increased sales of high-margin products and a reduced burden from inventory valuation and disposal losses related to MOBI-C contributed to the improvement in cumulative operating profit.


Its subsidiary Intro BioPharma remained profitable despite a challenging business environment, including changes to the drug pricing system and rising raw material costs. On a cumulative standalone basis, revenue for the first three quarters was KRW 12.6 billion, operating profit was KRW 900 million, and net income was KRW 1.3 billion.



A company official said, "Steady sales of key products and an improved cost ratio supported the increase in cumulative operating profit. We will manage the profitability of our existing businesses while developing our medical robotics business as a mid- to long-term growth driver."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing